Orion continues development of inhalable budesonide-formoterol combined formulation
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 7 FEBRUARY 2012 at 9.35 EET
Orion Corporation is developing a budesonide-formoterol formulation that
combines budesonide as an anti-inflammatory agent and formoterol as a long-
acting bronchodilator to broaden the range of the inhalable Easyhaler(®) drugs
product family. Study results received early in 2012 were promising, but yet
insufficient for submission of an application for marketing authorisation. The
Company will continue development of the product in 2012.
The studies showed that the combined formulation developed by Orion used with
Easyhaler device has consistent dose delivery. However, equivalence with the
reference product, which is required under the guideline of the European
Medicines Agency, was not reached in the studies.
Encouraged by the progress achieved in the research programme, Orion continues
development of the budesonide-formoterol combined formulation as originally
planned and will commence new studies on the product from which conclusions can
be drawn in the first half of 2013.
In addition, Orion has another Easyhaler research programme in progress to
develop a fluticasone-salmeterol combined formulation. In this combined
formulation fluticasone acts as an anti-inflammatory agent and salmeterol acts
as a long-acting bronchodilator.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior Vice President, Corporate Functions
Contact person:
Reijo Salonen, Senior Vice President, Pharmaceuticals Research and Development,
phone +358 50 966 3647
Publisher:
Orion Corporation
www.orion.fi/en
Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, oncology and critical care drugs, and Easyhaler®
pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested
EUR 86 million in research and development. At the end of 2010, the Group had
about 3,100 employees, of whom 2,500 worked in Finland and the rest in other
countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1583125]
Unternehmensinformation / Kurzprofil:
Datum: 07.02.2012 - 08:35 Uhr
Sprache: Deutsch
News-ID 111620
Anzahl Zeichen: 3367
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion continues development of inhalable budesonide-formoterol combined formulation"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
